Drugs / Recombinant Antihemophilic Factor
Recombinant Antihemophilic Factor
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT00189982 | Dec 2004 → Nov 2006 | hemophilia A | Baxalta now part of Shire | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-12-01 | Takeda | Results Initial Data from Shire Collaboration Identifies Key Biomarkers That Affect Bleeding Patterns, Response to Treatment for Hemophilia A takeda.com ↗
The study also supports the feasibility of using limited, 2-sample PK profiling to capture accurate PK curves that can then be utilized to guide individualized, PK-guided prophylaxis. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-12-01 | Takeda | Initial Data from Shire Collaboration Identifies Key Biomarkers That Affect Bleeding Patterns, Response to Treatment for Hemophilia A takeda.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Antihemophilic Factor | “Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (ADVATE rAHF-PFM): Safety Monitoring in Pediatric Patients Diagnosed With...” NCT00189982 ↗ |
| Known as | ADVATE rAHF-PFM | “Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (ADVATE rAHF-PFM): Safety Monitoring in Pediatric Patients Diagnosed With...” NCT00189982 ↗ |
| Known as | rAHF-PFM | “Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)” NCT00189982 ↗ |